Knorr, Katherine
Rahman, Jahan
Erickson, Caroline
Wang, Eric
Monetti, Mara
Li, Zhuoning
Ortiz-Pacheco, Juliana
Jones, Andrew
Lu, Sydney X.
Stanley, Robert F.
Baez, Maria
Fox, Nina
Castro, Cynthia
Marino, Alessandra E.
Jiang, Caroline
Penson, Alex http://orcid.org/0000-0003-2429-2370
Hogg, Simon J. http://orcid.org/0000-0002-3170-839X
Mi, Xiaoli
Nakajima, Hideaki http://orcid.org/0000-0002-8967-4954
Kunimoto, Hiroyoshi
Nishimura, Koutarou
Inoue, Daichi http://orcid.org/0000-0002-7947-6540
Greenbaum, Benjamin http://orcid.org/0000-0001-6153-8793
Knorr, David
Ravetch, Jeffrey http://orcid.org/0000-0003-2024-9041
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA251138, R01 CA242020, P50 CA254838, CCSG, P30 CA08748, P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128239)
Leukemia and Lymphoma Society
Edward P. Evans Foundation
American Society of Hematology
American Society of Clinical Oncology
Doris Duke Charitable Foundation
Article History
Received: 18 November 2022
Accepted: 19 September 2023
First Online: 23 October 2023
Competing interests
: The authors declare the following competing interests: B.G. has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies and Rome Therapeutics of which he is a co-founder. O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine, Merck, Prelude Therapeutics and Janssen and is on the scientific advisory board of Envisagenics, AIChemy, Harmonic Discovery and Pfizer Boulder; O.A.-W. has received prior research funding from H3B Biomedicine, Nurix Therapeutics, Minovia Therapeutics and Loxo Oncology unrelated to the current paper. The remaining authors declare no competing interests. The remaining authors have nothing to disclose.